本页面由Tiger Trade Technology Pte. Ltd.提供服务

Ultragenyx Pharmaceutical Inc

16.48
-0.7400-4.30%
盘后:16.500.0200+0.12%19:31 EST
成交量:301.02万
成交额:5,001.91万
市值:16.80亿
市盈率:-3.18
高:17.35
开:16.94
低:16.43
收:17.22
52周最高:39.89
52周最低:12.73
股本:1.02亿
流通股本:7,773.53万
量比:0.72
换手率:3.87%
股息:- -
股息率:- -
每股收益(TTM):-5.1758
每股收益(LYR):-5.8316
净资产收益率:-608.47%
总资产收益率:-22.98%
市净率:-4.47
市盈率(LYR):-2.83

数据加载中...

2026/11/13

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/11/10

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/11/04

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/11/04

重要事件披露

Form 8-K - Current report
2026/10/30

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/10/20

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/10/19

重要事件披露

Form 8-K - Current report
2026/10/14

重要事件披露

Form 8-K - Current report
2026/10/07

重要事件披露

Form 8-K - Current report
2026/09/17

重要事件披露

Form 8-K - Current report
2026/09/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/09/03

重要事件披露

Form 8-K - Current report
2026/08/19

重要事件披露

Form 8-K - Current report
2026/08/14

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/08/13

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/08/11

重要事件披露

Form 8-K - Current report
2026/08/07

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/08/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/05

重要事件披露

Form 8-K - Current report
2026/08/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities